OTCMKTS:CYTR LadRx (CYTR) Stock Price, News & Analysis Add Compare Share Share Today's Range N/A50-Day Range$0.09▼$0.0952-Week Range N/AVolume4,000 shsAverage Volume99,706 shsMarket Capitalization$4.14 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get LadRx alerts: Email Address Ad Weiss RatingsNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Find out details on these three critical Nvidia partners immediately. About LadRx Stock (OTCMKTS:CYTR)LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.Read More Ad Weiss RatingsNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Find out details on these three critical Nvidia partners immediately. CYTR Stock News HeadlinesJuly 19, 2024 | seekingalpha.comNasdaq Korea Consumer Staples Index (NQKR45:IND) Stock Price, Quote, News & Analysis - Seeking AlphaMay 17, 2024 | finance.yahoo.comLadRx Corporation (LADX)July 26, 2024 | DTI (Ad)We’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! August 11, 2023 | finance.yahoo.comLadRx Corporation (LADX) Stock Historical Prices & Data - Yahoo FinanceNovember 27, 2022 | finance.yahoo.comLadRx Corporation Issues Corporate Update for 3Q22October 5, 2022 | businesswire.comLadRx Corporation Announces OTCQB Ticker Change to LADX - Business WireSeptember 23, 2022 | marketscreener.comCYTRX CORP : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) - Marketscreener.comSeptember 23, 2022 | businesswire.comCytRx Corporation Relaunches as LadRx Corporation - Business WireJuly 26, 2024 | DTI (Ad)We’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! September 7, 2022 | businesswire.comEuropean Patent Office Awards CytRx Key Patent - Business WireAugust 25, 2022 | marketscreener.comADIAL PHARMACEUTICALS, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K) - Marketscreener.comAugust 21, 2022 | reuters.comCYTR.PK - CytRx Corporation | Stock Price & Latest News | ReutersAugust 9, 2022 | businesswire.comCytRx Welcomes Cary J. Claiborne to the CytRx Board of Directors - Business WireAugust 9, 2022 | finance.yahoo.comCytRx Welcomes Cary J. Claiborne to the CytRx Board of DirectorsJuly 27, 2022 | marketscreener.comCYTRX CORP : Submission of Matters to a Vote of Security Holders (form 8-K) - Marketscreener.comMay 20, 2022 | stockhouse.com2022-05-19 | OTCQB:CYTR | Press Release | CytRx Corporation - StockhouseMay 20, 2022 | businesswire.comCytRx Announces Distribution of Series D Preferred Stock to Holders of Its Common Stock - Business WireMay 20, 2022 | marketscreener.comCYTRX CORP : Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) - Marketscreener.comSee More Headlines Receive CYTR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LadRx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/09/2019Today7/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolOTCMKTS:CYTR CUSIPN/A CIK799698 Webwww.cytrx.com Phone(310) 826-5648Fax310-826-6139Employees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,700,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-67.61% Return on Assets-45.39% Debt Debt-to-Equity RatioN/A Current Ratio5.94 Quick Ratio5.94 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.24 per share Price / BookN/AMiscellaneous Outstanding Shares45,037,000Free Float33,834,000Market Cap$4.14 million OptionableNot Optionable Beta1.96 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. John Y. Caloz (Age 70)CFO, Treasurer & Sr. VP Comp: $500kDr. Stephen Snowdy Ph.D. (Age 52)Chief Exec. Officer Molly Carey PoarchGlobal & U.S. Head of Corp. CommunicationsMs. Molly Painter (Age 46)Pres of USA and Head of Launch & Commercial Operations Terri StevensChief Bus. OfficerMs. Cristina NewmanCorp. Sec.Dr. Felix Kratz Ph.D. (Age 59)Sr. VP, Drug Devel. More ExecutivesKey CompetitorsBiomXNYSEAMERICAN:PHGEEvaxion Biotech A/SNASDAQ:EVAXAptose BiosciencesNASDAQ:APTOInhibikase TherapeuticsNYSE:IKTSenti BiosciencesNASDAQ:SNTIView All Competitors CYTR Stock Analysis - Frequently Asked Questions How were LadRx's earnings last quarter? LadRx Co. (OTCMKTS:CYTR) announced its quarterly earnings results on Friday, August, 9th. The biotechnology company reported ($0.04) EPS for the quarter, topping analysts' consensus estimates of ($0.06) by $0.02. When did LadRx's stock split? Shares of LadRx reverse split on the morning of Wednesday, November 1st 2017. The 1-6 reverse split was announced on Friday, October 27th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 31st 2017. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split. How do I buy shares of LadRx? Shares of CYTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of LadRx own? Based on aggregate information from My MarketBeat watchlists, some other companies that LadRx investors own include Anavex Life Sciences (AVXL), Biopharmx (BPMX), Rexahn Pharmaceuticals (REXN), Idera Pharmaceuticals (IDRA), Arrowhead Pharmaceuticals (ARWR) and Aurinia Pharmaceuticals (AUPH). This page (OTCMKTS:CYTR) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LadRx Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share LadRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.